P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer

P-cadherin is a calcium-dependent cell–cell adhesion glycoprotein. P-cadherin expression is restricted to the myoepithelial cells in normal breast tissue, and aberrant staining has also been described in invasive tumors. Several small studies have reported P-cadherin as a marker of poor outcome in breast cancer patients but its prognostic significance in relation to other variables has not been established in a large series of breast cancers. A tissue microarray was constructed from 3992 cases of invasive breast carcinoma, and P-cadherin expression was evaluated using immunohistochemistry. Median follow-up was 12.5 years. The immunohistochemistry-based definitions of cancer subtypes were luminal (ER+ or PR+/HER2−), luminal/HER2+ (ER+ or PR+/HER2+), HER2+ (ER−/PR−/HER2+), and basal (ER−/PR−/HER2−/CK5/6+ or EGFR+). Clinical covariate and biomarker associations were assessed using contingency tables, and Pearson's χ2 or Fisher's exact test. Survival associations were assessed using Kaplan–Meier plots, logrank and Breslow tests, and Cox proportional hazards regression analysis. P-cadherin was expressed in 34.8% (1290/3710, 50% cut point) of cases. P-cadherin staining was strongly associated with HER2+ and basal carcinoma subtypes (P<0.0005). P-cadherin-positive patients showed significantly poorer short-term (0–10 years) overall survival, disease-specific survival, distant relapse-free interval, and locoregional relapse-free interval in univariable models (P<0.05). In multivariable Cox models containing standard clinical covariates and cancer subtypes, P-cadherin did not show independent prognostic value. P-cadherin expression was positively associated with histological grade, chemotherapy, Ki-67, EGFR, CK5/6, p53, YB-1, and HER2 expression (P<0.002), and negatively associated with age at diagnosis, ER, PR, and Bcl-2 expression (P<0.0005). This study shows the value of P-cadherin as a marker of poor prognosis. The large sample size of this series clarifies contradictory findings of many smaller studies. P-cadherin positivity is associated with high-grade tumor subtypes and well-established markers of poor prognosis, and may represent a promising antibody therapeutic target.

[1]  A. P. Soler,et al.  Soluble p-cadherin found in human semen. , 2005, Journal of andrology.

[2]  S. Leung,et al.  Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients , 2009, Breast Cancer Research and Treatment.

[3]  K. Knudsen,et al.  Cadherins and the mammary gland , 2005, Journal of cellular biochemistry.

[4]  L. Akslen,et al.  Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Daniel Zelterman,et al.  Modeling Survival Data: Extending the Cox Model , 2002, Technometrics.

[6]  A. P. Soler,et al.  P‐cadherin expression in breast carcinoma indicates poor survival , 1999, Cancer.

[7]  J. Cigudosa,et al.  Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers , 2005, Breast Cancer Research and Treatment.

[8]  D. Easton,et al.  Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.

[9]  G. Gómez-López,et al.  Functional characterization of E- and P-cadherin in invasive breast cancer cells , 2009, BMC Cancer.

[10]  F. Schmitt,et al.  p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas , 2005, Virchows Archiv.

[11]  T. Hastie,et al.  New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up , 2008, Breast Cancer Research and Treatment.

[12]  Heinz Höfler,et al.  Mutations of the human E‐cadherin (CDH1) gene , 1998, Human mutation.

[13]  M. Troxell,et al.  Immunohistochemical Staining of Papillary Breast Lesions , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[14]  T. Nielsen,et al.  Tissue microarrays in clinical oncology. , 2008, Seminars in radiation oncology.

[15]  B. Boyer,et al.  Induction and regulation of epithelial-mesenchymal transitions. , 2000, Biochemical pharmacology.

[16]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[17]  J. Cigudosa,et al.  Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  B. Rubino,et al.  The role of epithelial-mesenchymal transition in cancer pathology. , 2007, Pathology.

[19]  L. Chodosh,et al.  Precocious Mammary Gland Development in P-Cadherin–deficient Mice , 1997, The Journal of cell biology.

[20]  Yusuke Nakamura,et al.  Identification of a Novel Tumor-Associated Antigen, Cadherin 3/P-Cadherin, as a Possible Target for Immunotherapy of Pancreatic, Gastric, and Colorectal Cancers , 2008, Clinical Cancer Research.

[21]  I. Ellis,et al.  Expression of BRCA1 protein in breast cancer and its prognostic significance. , 2008, Human pathology.

[22]  K. Toda,et al.  Roles of E‐ and P‐cadherin in the human skin , 1997, Microscopy research and technique.

[23]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[24]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[25]  F. Schmitt,et al.  P-cadherin expression in breast cancer: a review , 2007, Breast Cancer Research.

[26]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[27]  O. De Wever,et al.  Soluble N‐cadherin in human biological fluids , 2006, International journal of cancer.

[28]  Carmen Jerónimo,et al.  P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation , 2005, Clinical Cancer Research.

[29]  J. Espada,et al.  Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. , 1995, The American journal of pathology.

[30]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[31]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[32]  B. Gusterson.  Do 'basal-like' breast cancers really exist? , 2009, Nature Reviews Cancer.

[33]  A. Signy.  MODERN PATHOLOGY , 1960 .

[34]  R. Walker,et al.  Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas , 2003 .

[35]  H. Putter,et al.  The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer , 2007, Breast Cancer Research and Treatment.

[36]  P. Bossuyt,et al.  Reporting bias in diagnostic and prognostic studies: time for action. , 2008, Clinical chemistry.

[37]  Yasodha Natkunam,et al.  TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays , 2005, Modern Pathology.

[38]  R. Seruca,et al.  Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells , 2010, Oncogene.

[39]  F. Walsh,et al.  Epithelial (E‐) and placentae (P‐) cadherin cell adhesion molecule expression in breast carcinoma , 1993, The Journal of pathology.

[40]  Y. Horiguchi,et al.  Cadherins in Cutaneous Biology , 1994, The Journal of dermatology.

[41]  E. Wilkinson,et al.  Molecular and Morphologic Distinctions between Infiltrating Ductal and Lobular Carcinoma of the Breast , 2007, The breast journal.

[42]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[43]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[44]  D. Birnbaum,et al.  Typical medullary breast carcinomas have a basal/myoepithelial phenotype , 2005, The Journal of pathology.

[45]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[47]  J. Reis-Filho,et al.  Novel and Classic Myoepithelial/Stem Cell Markers in Metaplastic Carcinomas of the Breast , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[48]  A. Gown,et al.  Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Reis-Filho,et al.  Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer? , 2002, Pathology, research and practice.

[50]  S. Leung,et al.  Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases , 2007, Breast Cancer Research and Treatment.

[51]  Samuel Leung,et al.  Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes , 2008, Breast Cancer Research.

[52]  P. Jensen,et al.  Inhibition of cadherin function differentially affects markers of terminal differentiation in cultured human keratinocytes. , 1999, Journal of cell science.

[53]  S. Lakhani,et al.  Metaplastic breast carcinomas are basal‐like tumours , 2006, Histopathology.

[54]  E. Sauter,et al.  Increased shedding of soluble fragments of P‐cadherin in nipple aspirate fluids from women with breast cancer , 2008, Cancer science.

[55]  L. Akslen,et al.  Frequency of the basal‐like phenotype in African breast cancer , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[56]  J. Russo,et al.  Soluble fragment of P‐cadherin adhesion protein found in human milk , 2002, Journal of cellular biochemistry.

[57]  Lloyd D. Fisher,et al.  Biostatistics: A Methodology for the Health Sciences , 1993 .

[58]  A. Ashworth,et al.  A mouse model of basal‐like breast carcinoma with metaplastic elements , 2007, The Journal of pathology.

[59]  T. Nielsen,et al.  Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer , 2008, Journal of Clinical Pathology.

[60]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[61]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[62]  J. Saurat,et al.  Terminal differentiation in cultured human keratinocytes is associated with increased levels of cellular retinoic acid-binding protein. , 1988, Experimental cell research.

[63]  S. Leung,et al.  Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study , 2008, Breast Cancer Research.

[64]  A. P. Soler,et al.  Lack of correlation between serum levels of E- and P-cadherin fragments and the presence of breast cancer. , 2000, Human pathology.

[65]  G. Moreno-Bueno,et al.  The Prognostic Significance of P-Cadherin in Infiltrating Ductal Breast Carcinoma , 2001, Modern Pathology.

[66]  R. Walker,et al.  Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas , 2003, Molecular pathology : MP.

[67]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[68]  F. Schmitt,et al.  Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival , 2008, Journal of Clinical Pathology.

[69]  Kelli Montgomery,et al.  Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis , 2009, BMC Cancer.

[70]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[71]  F. Schmitt,et al.  P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ , 2006, Virchows Archiv.

[72]  R. Walker,et al.  P-cadherin as a marker in the differential diagnosis of breast lesions , 2003, Journal of clinical pathology.

[73]  L. Akslen,et al.  Independent prognostic value of the basal‐like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI‐1 , 2008, Histopathology.

[74]  N Harbeck,et al.  Triple-negative breast cancer--current status and future directions. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[76]  J. Benítez,et al.  The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications , 2005, Modern Pathology.

[77]  W. Foulkes,et al.  A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors , 2005, Cancer Epidemiology Biomarkers & Prevention.

[78]  Karen A Gelmon,et al.  Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  A. Cleton-Jansen.  E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? , 2001, Breast Cancer Research.

[80]  W. Storkus,et al.  A 'good death' for tumor immunology , 2007, Nature Medicine.

[81]  T. Rowlands,et al.  Cadherins and catenins in breast cancer. , 2005, Current opinion in cell biology.

[82]  A. P. Soler,et al.  Distinct cadherin profiles in special variant carcinomas and other tumors of the breast. , 1999, Human pathology.

[83]  Ash A. Alizadeh,et al.  Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. , 2002, The American journal of pathology.

[84]  Robert Tibshirani,et al.  The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd Edition , 2001, Springer Series in Statistics.

[85]  Daniel Birnbaum,et al.  Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin , 2008, BMC Cancer.

[86]  A. Nose,et al.  Isolation of placental cadherin cDNA: identification of a novel gene family of cell‐cell adhesion molecules. , 1987, The EMBO journal.

[87]  A. Tutt,et al.  Triple negative tumours: a critical review , 2007, Histopathology.

[88]  P. Balaram,et al.  Cadherins as Predictive Markers of Nodal Metastasis in Breast Cancer , 2001, Modern Pathology.

[89]  L. Bégin,et al.  Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer , 2005, Clinical Cancer Research.